ArticleAnnals of hematology2025
First report of B-lymphoblastic leukemia harboring LRRFIP1::FGFR1 fusion: expanding the clinical spectrum of myeloid/lymphoid neoplasms with tyrosine kinase gene fusions.
Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions (MLN-TK) are rare hematologic malignancies defined by recurrent kinase gene rearrangements. FGFR1 is a well-recognized partner in this category, but de novo B-lymphoblastic leukemia (B-ALL) as the initial presentation remains exceedingly rare. We report the first case of B-ALL with an LRRFIP1::FGFR1 fusion, identified by whole transcriptome sequencing in a 62-year-old male. The patient achieved sustained complete remission following intensive chemotherapy without hematopoietic stem cell transplantation. Only two prior cases of LRRFIP1::FGFR1 fusion have been reported, both presenting as acute myeloid leukemia. All three cases share an identical fusion structure. This case expands the clinical and molecular spectrum of FGFR1-rearranged neoplasms and underscores the importance of comprehensive molecular profiling for accurate classification, risk assessment, and individualized therapeutic planning in MLN-TK.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.